Bio Path Holdings Inc To Discuss Advances in the Treatment Landscape for Acute Myeloid Leukemia Transcript
(Operator Instructions) Good morning, ladies and gentlemen, and welcome to the Bio Path Holdings conference call. (Operator Instructions) This call is being recorded. I would now like to turn the call over to Will O'Connor of Stern Investor Relations. Please proceed.
' -
Thank you, operator. Welcome to the Bio Path Holdings Key Opinion Leader conference call to discuss proxy diversion and advances in the Treatment Landscape for Acute Myeloid Leukemia . Before we begin the call, I'd like to remind you that today's discussion will contain four looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in the company's recent filings with the Securities and Exchange Commission, which we urge you to read.
Our actual results may differ materially from what is discussed on today's call. With me today from Bio Path are President and CEO Peter Nielsen and Senior Vice President of Research, Development, and Clinical Design, Dr. Ana Tari Ashizawa. Following
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |